{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:48:38Z","timestamp":1789760918431,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajpc.2026.101655","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:31:14Z","timestamp":1779690674000},"page":"101655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cardiovascular event rate modifies response to pharmacologic LDL-C lowering in primary prevention: implications of a systematic review and meta-analysis for clinical practice"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3832-0734","authenticated-orcid":false,"given":"Irene","family":"Karungi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe A.T.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brandts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ajpc.2026.101655_bib0001","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and Risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10258","key":"10.1016\/j.ajpc.2026.101655_bib0002","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ajpc.2026.101655_bib0003","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults","volume":"338","author":"Berenson","year":"1998","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101655_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0002-9149(92)90726-F","article-title":"Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study)","volume":"70","author":"Berenson","year":"1992","journal-title":"Am J Cardiol"},{"issue":"32","key":"10.1016\/j.ajpc.2026.101655_bib0005","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101655_bib0006","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMra2405153","article-title":"The inherited basis of coronary artery disease","volume":"394","author":"Schunkert","year":"2026","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ajpc.2026.101655_bib0007","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic risk, adherence to a healthy lifestyle, and coronary disease","volume":"375","author":"Khera","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajpc.2026.101655_bib0008","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"7855","key":"10.1016\/j.ajpc.2026.101655_bib0009","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"issue":"9493","key":"10.1016\/j.ajpc.2026.101655_bib0010","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101655_bib0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/ATVBAHA.123.320065","article-title":"Eradicating atherosclerotic events by targeting early subclinical disease: it is time to retire the therapeutic paradigm of too much, too late","volume":"44","author":"Williams","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"42","key":"10.1016\/j.ajpc.2026.101655_bib0012","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101655_bib0013","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/HCO.0000000000000911","article-title":"Evaluation of coronary stenosis versus plaque burden for atherosclerotic cardiovascular disease risk assessment and management","volume":"36","author":"Dzaye","year":"2021","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101655_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11444","article-title":"Association of cardiovascular disease risk factor burden with progression of coronary atherosclerosis assessed by serial coronary computed tomographic angiography","volume":"3","author":"Han","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101655_bib0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jacc.2021.10.035","article-title":"Coronary atherosclerotic plaque regression","volume":"79","author":"Dawson Luke","year":"2022","journal-title":"JACC"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101655_bib0016","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of Rosuvastatin on progression of carotid intima-Media thickness in low-risk individuals with subclinical AtherosclerosisThe METEOR trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101655_bib0017","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1177\/2047487312451539","volume":"20","author":"Ikeda","year":"2013","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101655_bib0018","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ajpc.2026.101655_bib0019","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101655_bib0020","first-page":"1308","article-title":"Effect of Evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"9841","key":"10.1016\/j.ajpc.2026.101655_bib0021","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/j.ajpc.2026.101655_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2026.02.006","article-title":"Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: a meta-analysis","author":"Kalra","year":"2026","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101655_bib0023","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/aje\/kwj062","article-title":"Limits to causal inference based on mendelian randomization: a comparison with randomized controlled trials","volume":"163","author":"Nitsch","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101655_bib0024","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ajpc.2026.101655_bib0025","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001423","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Writing Committee Members","year":"2026","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101655_bib0026","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/jamainternmed.2022.0134","article-title":"Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of Statin treatment: a systematic review and meta-analysis","volume":"182","author":"Byrne","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ajpc.2026.101655_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111327","article-title":"Hierarchical models that address measurement error are needed to evaluate the correlation between treatment effect and control group event rate","volume":"170","author":"Murad","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ajpc.2026.101655_bib0028","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PriSMa 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ajpc.2026.101655_bib0029","first-page":"372","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ajpc.2026.101655_bib0030","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101655_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.ajpc.2026.101655_bib0032","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2026.3277","article-title":"Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial","volume":"35","author":"Marston","year":"2026","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ajpc.2026.101655_bib0033","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ajpc.2026.101655_bib0034","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol LevelsResults of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"9346","key":"10.1016\/j.ajpc.2026.101655_bib0035","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"The Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.ajpc.2026.101655_bib0036","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","volume":"64","author":"Sever","year":"2004","journal-title":"Drugs"},{"issue":"9435","key":"10.1016\/j.ajpc.2026.101655_bib0037","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"The Lancet"},{"issue":"9542","key":"10.1016\/j.ajpc.2026.101655_bib0038","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101655_bib0039","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.ajpc.2026.101655_bib0040","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ajpc.2026.101655_bib0041","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"issue":"9784","key":"10.1016\/j.ajpc.2026.101655_bib0042","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101655_bib0043","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jvs.2016.07.054","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"64","author":"Yusuf","year":"2016","journal-title":"J Vasc Surg"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101655_bib0044","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamainternmed.2017.1442","article-title":"Effect of Statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial","volume":"177","author":"Han","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101655_bib0045","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/art.40892","article-title":"A multicenter, randomized, placebo-controlled trial of Atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis","volume":"71","author":"Kitas","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101655_bib0046","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ajpc.2026.101655_bib0047","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036357","article-title":"Baseline characteristics of participants in STAREE: a randomized trial for primary prevention of cardiovascular disease events and prolongation of disability-free survival in older people","volume":"13","author":"Zoungas","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101655_bib0081","first-page":"8","article-title":"A prospective study of pravastatin in the elderly at risk (PROSPER): screening experience and baseline characteristics","volume":"3","author":"Ford","year":"2002","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"20","key":"10.1016\/j.ajpc.2026.101655_bib0082","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/CIRCULATIONAHA.104.526848","article-title":"Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective study of pravastatin in the elderly at risk (PROSPER)","volume":"112","author":"Packard","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2026.101655_bib0083","unstructured":"Nissen S.E. Data-on-file 1002-043 MACE-4, MACE-and MACE components for primary prevention patients (Full Analysis Set). Unpublished data; 2024."},{"issue":"2","key":"10.1016\/j.ajpc.2026.101655_bib0057","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","article-title":"Comparative cardiovascular benefits of Bempedoic acid and Statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"JACC"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101655_bib0048","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.atherosclerosis.2014.05.003","article-title":"Attainment of the anticipated >=50% reduction in LDL-C in the four ACC\/AHA guidelines statin benefit groups: a voyager meta-analysis","volume":"235","author":"Karlson","year":"2014","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101655_bib0049","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/eurheartj\/ehr262","article-title":"Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"33","author":"Sever","year":"2012","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.ajpc.2026.101655_bib0050","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","article-title":"Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome","volume":"55","author":"Nicholls","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101655_bib0051","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary AtherosclerosisA randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.ajpc.2026.101655_bib0052","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary AtherosclerosisThe ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ajpc.2026.101655_bib0053","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101655_bib0054","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejim.2024.08.010","article-title":"The clinical relevance of the reversal of coronary atherosclerotic plaque","volume":"129","author":"Cesaro","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ajpc.2026.101655_bib0055","doi-asserted-by":"crossref","unstructured":"Fanaroff A.C., Roe M.T., Clare R.M., et al. Competing risks of cardiovascular versus noncardiovascular death during long-term follow-up after acute coronary syndromes. J Am Heart Assoc. 6(9):e005840.","DOI":"10.1161\/JAHA.117.005840"},{"issue":"27","key":"10.1016\/j.ajpc.2026.101655_bib0056","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101655_bib0058","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ajpc.2026.101655_bib0059","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamacardio.2019.2851","article-title":"Cost-effectiveness of low-density lipoprotein cholesterol level-guided statin treatment in patients with borderline cardiovascular risk","volume":"4","author":"Kohli-Lynch","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"79","key":"10.1016\/j.ajpc.2026.101655_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/KDAP7034","article-title":"Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets","volume":"28","author":"Mihaylova","year":"2024","journal-title":"Health Technol Assess"},{"issue":"27","key":"10.1016\/j.ajpc.2026.101655_bib0061","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/eurheartj\/ehx710","article-title":"Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies","volume":"39","author":"Annemans","year":"2018","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.ajpc.2026.101655_bib0062","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101655_bib0063","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ajpc.2026.101655_bib0064","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"Supplement 2","key":"10.1016\/j.ajpc.2026.101655_bib0065","article-title":"Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab","volume":"43","author":"Michaeli","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2026.101655_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)00419-8","article-title":"Early atheroma prevention: a cost-effective approach to healthy cardiovascular ageing","author":"Steinhauer","year":"2026","journal-title":"The Lancet"},{"issue":"13","key":"10.1016\/j.ajpc.2026.101655_bib0067","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski Michael","year":"2020","journal-title":"JACC"},{"key":"10.1016\/j.ajpc.2026.101655_bib0068","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/PPA.S502645","article-title":"A systematic review uncovering modifiable influences on Statin adherence","volume":"19","author":"Rosenberg","year":"2025","journal-title":"Patient Prefer Adherence"},{"issue":"21","key":"10.1016\/j.ajpc.2026.101655_bib0069","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jacc.2025.09.1509","article-title":"Age and sex-specific percentiles of 30-year cardiovascular disease risk based on the PREVENT equations","volume":"86","author":"Krishnan","year":"2025","journal-title":"JACC"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101655_bib0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajpc.2026.101655_bib0071","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.athplu.2024.10.001","article-title":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: a systematic review of randomised controlled trials","volume":"58","author":"Iannuzzo","year":"2024","journal-title":"Atheroscler Plus"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101655_bib0072","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5334\/gh.1154","article-title":"World Heart Federation cholesterol Roadmap 2022","volume":"17","author":"Ray","year":"2022","journal-title":"Glob Heart"},{"issue":"9374","key":"10.1016\/j.ajpc.2026.101655_bib0073","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"The Lancet"},{"key":"10.1016\/j.ajpc.2026.101655_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100957","article-title":"Generalizability of VICTORION-1 PREVENT enrollment criteria to the United States population","volume":"22","author":"Aggarwal","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ajpc.2026.101655_bib0075","unstructured":"Merck Sharp & Dohme LLC. Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes. ClinicalTrials.gov identifier: NCT06008756. Updated December 13, 2025. Accessed April 29, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06008756."},{"issue":"2","key":"10.1016\/j.ajpc.2026.101655_bib0076","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ajpc.2026.101655_bib0077","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease","volume":"322","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.ajpc.2026.101655_bib0078","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726002308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726002308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:28:22Z","timestamp":1787689702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726002308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":81,"alternative-id":["S2666667726002308"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101655","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular event rate modifies response to pharmacologic LDL-C lowering in primary prevention: implications of a systematic review and meta-analysis for clinical practice","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101655"}}